"Process For Preparation Of Novel Polymorphic Forms Of Regadenoson"

Enaltec Labs Private Limited
Granted App No 1470/MUM/2011 Patent 396353 Pharmaceuticals

Patent information

IP India · live record
Application number
1470/MUM/2011
Filing date
13 May 2011
Status
Granted
Legal status
Ceased
Publication number
49/2012
Publication type
INA
Invention field
Pharmaceuticals
Patent number
396353
Grant date
06 May 2022
Next renewal due
13 May 2024Overdue

Abstract

The present invention provides polymorphic form of regadenoson and its acid addition salts selected from the group comprising of regadenoson hydrochloride, regadenoson hydrobromide, regadenoson maleate, regadenoson fumarate, regadenoson succinate, regadenoson sulfate, regadenoson acetate, regadenoson mesylate, regadenoson tartrate or regadenoson* lactate.

Applicants

1
India
ENALTEC LABS PRIVATE LIMITED 17TH FLOOR, KESAR SOLITAIRE, PLOT NO.5 SECTOR-19, SANPADA, NAVI MUMBAI MAHARASHTRA, INDIA. PIN CODE:400705

Inventors

5
India
SIVA KUMAR VENKATA BOBBAENALTEC LABS PRIVATE LIMITED, PLOT NO.W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE-421506, MAHARASHTRA, INDIA
India
ESWARA RAO KODALIENALTEC LABS PRIVATE LIMITED, PLOT NO.W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE-421506, MAHARASHTRA, INDIA
India
GIRISH BANSILAL PATELENALTEC LABS PRIVATE LIMITED, PLOT NO.W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE-421506, MAHARASHTRA, INDIA
India
SANJAY DASHRATH VAIDYAENALTEC LABS PRIVATE LIMITED, PLOT NO.W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE-421506, MAHARASHTRA, INDIA
India
ALOK PRAMOD TRIPATHIENALTEC LABS PRIVATE LIMITED, PLOT NO.W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE-421506, MAHARASHTRA, INDIA

Claims

10
1 Regadenoson crystalline form D characterized by having moisture content less than 0.1% wt/wt.
2 Regadenoson crystalline form E characterized by having moisture content in the range of 2% wt/wt to 2.5% wt/wt.
3 Regadenoson crystalline form F characterized by having moisture content in the range of 6% wt/wt to 7.5% wt/wt.
4 Regadenoson crystalline form G characterized by having moisture content in the range of 8.0% wt/wt to 9.0% wt/wt.
5 Acid addition salts of regadenoson selected from the group comprising of regadenoson hydrochloride, regadenoson hydrobromide, regadenoson maleate, regadenoson fumarate, regadenoson succinate, regadenoson sulfate, regadenoson acetate, regadenoson mesylate, regadenoson tartrate or regadenoson lactate.
6 A pharmaceutical composition comprising crystalline form D, crystalline form E, crystalline form F, crystalline form G or amorphous form of regadenoson.
7 A process of preparing amorphous form of regadenoson by spray-drying or freeze-drying the solution of regadenoson in an organic solvent.
8 The process according to claim no. 7 wherein organic solvent is selected from the group comprising of ketones, alcohols, esters, nitriles, halogenated aliphatic hydrocarbon solvents, ethers or mixtures thereof.
9 Substantially pure regadenoson having HPLC purity greater than 99.0%.
10 A process of preparing substantially pure regadenoson comprising treating Acid addition salts of regadenoson selected from the group comprising of regadenoson hydrochloride, regadenoson hydrobromide, regadenoson maleate, regadenoson fumarate, regadenoson succinate, regadenoson sulfate, regadenoson acetate, regadenoson mesylate, regadenoson tartrate or regadenoson lactate with an inorganic base.

Specification

Show full textCollapse

FORM 2 THE PATENT ACT, 1970 (39 of 1970) & The Patents Rules, 2003 COMPLETE SPECIFICATION (See section 10 and rule 13) Title of the invention "NOVEL POLYMORPHIC FORMS OF REGADENOSON." Enaltec Labs Pvt. Ltd. an Indian Company, having its Registered Office at 17thFloor, Kesar Solitaire, Plot No.5 Sector-19, Sanpada, Navi Mumbai Maharashtra, India. Pin Code: 400705 1. The following specification particularly describes the invention and the manner in which it is to be performed.

NOVEL POLYMORPHIC FORMS OF REGADENOSON FIELD OF THE INVENTION: The present invention relates to novel polymorphic forms of regadenoson. The present invention further relates to processes of preparing novel polymorphic forms of regadenoson and pharmaceutical composition thereof. BACKGROUND OF THE INVENTION: Regadenoson is chemically adenosine, 2-[4-[(methylamino) carbonyl]-lH-pyrazol-l-yl] -or l-(6-amino-9-((3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-9H-purin-2-yl)-N-methyl-lH-pyrazole-4-carboxamide and is known from U.S. Patent No. 6,403,567 and is represented by compound of structural formula I.

Regadenoson has been approved in USA as regadenoson monohydrate and sold in market under the proprietary name LEX1SCAN. It is a pharmaceutical stress agent indicated for radionuclide myocardial perfusion imaging (MP1) in patients unable to undergo adequate exercise stress.

U.S. Patent No. 6,403,567 does not describe crystallization of regadenoson compound of structural formula I. U.S. Patent No. 7,671,192 discloses three different crystalline forms, referred to herein as monohydrate Form A, Form B, Form C, and an amorphous form of regadenoson compound of structural formula I. Regadenoson Form A is monohydrate form and can be produced by crystallizing regadenoson from protic solvents, for example ethanol or ethanol/water mixtures, or from a polar solvent, for example dimethylsulfoxide/water. Regadenoson Form B can be produced by evaporating under vacuum a solution of regadenoson in trifluoroethanol at ambient temperatures. The X-ray analysis of the crystals was distinctly different from any other polymorph, but it was difficult to determine its constitution, as the X-ray analysis gave disordered broad peaks, and the polymorph contained varying amounts of water. It was found to be difficult to reliably reproduce the preparation of this polymorph. Regadenoson Form C is an acetonitrile solvate and can be produced by slurrying regadenoson in acetonitrile for a long period of time at 60° C. The X-ray analysis of the crystals was distinctly different from any other polymorph. Regadenoson Polymorph C was shown to be a variable hydrate, which, at elevated temperatures, desolvates to an unstable form. Regadenoson amorphous form can be produced by heating Regadenoson Form A at a temperature of up to 200° C. This polymorph is unstable in the presence of atmospheric moisture, forming variable hydrates. The present applicant of the patent has surprisingly found that regadenoson can exist in anhydrous form and different hydrated forms. Thus the invention relates to novel

polymorphic forms of regadenoson i.e. anhydrous regadenoson, regadenoson hemihydrate, regadenoson sesquihydrate, and regadenoson dihydrate. SUMMARY OF THE INVENTION: A first aspect of the invention is to provide anhydrous form of regadenoson herein after referred as crystalline form D. A second aspect of the present invention is to provide hemihydrate form of regadenoson herein after referred as crystalline form E. A third aspect of the present invention is to provide sesquihydrate form of regadenoson herein after referred as crystalline form F. A fourth aspect of the present invention is to provide dihydrate form of regadenoson herein after referred as crystalline form G. Another aspect of the present invention is to provide acid addition salts of regadenoson. Another aspect of the present invention is to provide acid addition salts of regadenoson with an organic acid. Another aspect of the present invention is to provide acid addition salts of regadenoson with an inorganic acid. The acid addition salts of regadenoson may be selected from the group comprising of regadenoson hydrochloride, regadenoson hydrobromide, regadenoson maleate, regadenoson fumarate, regadenoson succinate, regadenoson sulfate, regadenoson acetate, regadenoson mesylate, regadenoson tartrate or regadenoson lactate.

Another aspect of the present invention is use of acid addition salts of regadenoson in purification of regadenoson. Another aspect of the present invention is use of acid addition salts of regadenoson in the preparation of amorphous form of regadenoson. Another aspect of the present invention present invention is to provide processes for the preparation of crystalline form D of regadenoson. The regadenoson form D may be prepared by azeotropic distillation of organic solvent from the solution of regadenoson in an organic solvent. Another aspect of the present invention present invention is to provide processes for the preparation of crystalline form E of regadenoson. Another aspect of the present invention present invention is to provide processes for the preparation of crystalline form F of regadenoson. Another aspect of the present invention present invention is to provide processes for the preparation of crystalline form G of regadenoson. Another aspect of the present invention present invention is to provide processes for the preparation of amorphous form of regadenoson. Another aspect of the present invention present invention is to provide pharmaceutical composition comprising crystalline form D, crystalline form E, crystalline form F, crystalline form G or amorphous form of regadenoson. The amorphous form of regadenoson may be prepared by spray-drying or freeze-drying the solution of regadenoson in an organic solvent.

The amorphous form of regadenoson may be prepared by concentrating the solution of regadenoson in an organic solvent under reduced pressure. DETAIL DESCRIPTION OF THE INVENTION: Regadenoson used for present invention may be formed by methods disclosed in the art such as those described in U.S. Patent Nos. 6,403,567; 7,671,192 which are incorporated herein by reference only. An anhydrous crystalline form D of regadenoson may be characterized by having moisture content less than 0.1% wt/wt. A crystalline form E of regadenoson hemihydrate may be characterized by having moisture content in the range of 2% wt/wt to 2.5% wt/wt. A crystalline form F of regadenoson sesquihydrate may be characterized by having moisture content in the range of 6% wt/wt to 7.5% wt/wt A crystalline form G of regadenoson dihydrate may be characterized by having moisture content in the range of 8.0% wt/wt to 9.0% wt/wt.. The crystalline form D of regadenoson may be formed by azeotropic distillation of organic solvent from the solution of regadenoson in an organic solvent. The solution of regadenoson in an organic solvent having moisture content in the range of 0.5% weight / weight to 8% weight / weight may be formed by dissolving regadenoson in an organic solvent at a temperature in the range of-10° to 60°C. The examples of organic solvent may include but not limited to alcohol solvents.

The examples of alcohol solvents may include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, pentanol or mixture(s) thereof. The crystalline form D of regadenoson may be isolated by the steps filtration, centrifugation, washing, drying or the combinations thereof. The crystalline form E of regadenoson may be isolated from the solution of regadenoson in an organic solvent having moisture content in the range of 2% wt/wt to 2.5% wt/wt at a temperature in the range of-5°C to 75°C. The examples of organic solvent may include but not limited to polar protic solvents. The example of polar protic solvents is selected from the group comprising of methanol, ethanol, n-propanol, isopropanol, n-butanol or mixture(s) thereof. The crystalline form E of regadenoson may be isolated by the steps filtration, centrifugation, washing, drying or the combinations thereof. The crystalline form F of regadenoson may be formed by treating a solution of regadenoson in an organic solvent with water at a temperature in the range of 0°C to 40°C. The solution of regadenoson in an organic solvent may be formed by dissolving regadenoson in an organic solvent at a temperature in the range of 20° to 60°C. The water used for the preparation of crystalline form F of regadenoson may be in the range 1.5 moles to 1.8 moles of regadenoson. The examples of organic solvent may include but not limited to alcohol solvents.

The examples of alcohol solvents may include methanol, ethanol, n-pfopanol, isopropanol, n-butanol, isobutanol, pentanol or mixture(s) thereof. The crystalline form F of regadenoson may be isolated by the steps filtration, centrifugation, washing, drying or the combinations thereof. The crystalline form G of regadenoson may be formed by treating a solution of regadenoson in an organic solvent with water at a temperature in the range of 0°C to 80°C. The solution of regadenoson in an organic solvent may be formed by dissolving regadenoson in an organic solvent at a temperature in the range of 0° to 80°C. The water used for the preparation of crystalline form F of regadenoson may be in the range 2.0 moles to 2.5 moles of regadenoson. The examples of organic solvent may include but not limited to alcohol solvents. The examples of alcohol solvents may include methanol, ethanol, n-pfopanol, isopropanol, n-butanol, isobutanol, pentanol or mixture(s) thereof. The crystalline form G of regadenoson may be isolated by the steps filtration, centrifugation, washing, drying or the combinations thereof. An amorphous form of regadenoson may be prepared by spray-drying or freeze-drying the solution of regadenoson in an organic solvent. A solution of regadenoson in organic solvents may be prepared by dissolving crystalline regadenoson in an organic solvent at a temperature in the range of 0°C to 75°C.

Alternatively, such a solution may be obtained directly from a reaction in which regadenoson is formed. Examples of organic solvent may include ketones, alcohols, esters, nitriles, halogenated aliphatic hydrocarbon solvents, ethers or mixtures thereof. The ketone solvents may be selected from the group comprising of acetone, methyl ethyl ketone, methyl isobutyl ketone, dibutyl ketone, diethyl ketone, dipropyl ketone, diisopropyl ketone, methyl butyl ketone, methyl propyl ketone, methyl isopropyl ketone, &k?j\ ".s^y-TOp^ ketone- os mvxtaire^s) \h«.rectf. The alcohol solvents may be selected from the group comprising of methanol, ethanol, propanol, isopropanol, butanol, isobutanol, t-butajiol, pentanol or mixture(s) thereof. The ester solvents may be selected from the group comprising of ethyl acetate, propyl acetate, isopropyl acetate; butyl acetate, tertiary butyl acetate, pentyl acetate or mixture(s) thereof. The nitrile solvents may be selected from the group comprising of acetonitrile, propionitrile or mixture(s) thereof. The halogenated aliphatic hydrocarbon solvents may be selected from the group comprising of dichloromethane, dichloroethane, chloroform, carbon tetrachloride or mixture(s) thereof. The ether solvents may be selected from the group comprising of tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, dibutyl ether, methyl tertiary butyl ether, methyl ethyl ether, methyl isobutyl ether or mixture(s) thereof. The solvent may be removed from the solution by a technique which includes, for example, spray drying and freeze drying.

In one aspect, regadenoson amorphous form may be recovered from the solution using a spray drying technique. A Mini-Spray Dryer (Model: Buchi 190, Switzerland) can be used. The Buchi 190 Mini-Spray Dryer operates on the principle of nozzle spraying in a parallel flow, i.e., the sprayed product and the drying gas flow in the same direction. The drying gas can be air or inert, gases such as nitrogen, argon and carbon dioxide. In another aspect, regadenoson amorphous form may be recovered from the solution using a freeze drying technique. A freeze dryer (Model; Virtis Genesis SQ Freeze Dryer) can be used in this technique. The Virtis Genesis SQ Freeze Dryer operates on the principle of lyophilization, i.e., a process of stabilizing initially wet materials (aqueous solution or suspensions) by freezing them, then subliming the ice while simultaneously desorbing some of the bound moisture (primary drying). Following removal of the ice, desorption may be continued (secondary drying). This process may be carried out under vacuum. The spray drying may be accomplished using a spray dryer which operates on the principle of nozzle spraying in a parallel flow, i.e., the sprayed product and the drying gas flow in the same direction. The drying gas can be air or one or more inert gases such as nitrogen, argon, and carbon dioxide. Moreover, the product obtained may be further or additionally dried to achieve the desired moisture values. For example, the product may be further or additionally dried in a tray drier, dried under vacuum and/or in a Fluid Bed Dryer. The acid addition salts of regadenoson may be selected from the group comprising of regadenoson hydrochloride, regadenoson hydrobromide, regadenoson maleate, regadenoson fumarate, regadenoson succinate, regadenoson sulfate, regadenoson acetate, regadenoson mesylate, regadenoson tartrate or regadenoson lactate. The salts of regadenoson compound of structural formula I with hydrochloric acid, hydrobromic acid, maleic acid, fumaric acid, succinic acid, sulphuric acid, acetic acid,

methanesulfonic acid, tartaric acid or lactic acid may be formed by reacting regadenoson compound of structural formula I with hydrochloric acid, hydrobromic acid, maleic acid, fumaric acid, succinic acid, sulphuric acid, acetic acid, methanesulfonic acid, tartaric acid or lactic acid in an organic solvent at a temperature in the range of 0°C to 30°C for a period of 30 minutes to 8 hours. The examples of organic solvent may include but not limited to alcohol solvents. The examples of alcohol solvents may include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, pentanol or mixture(s) thereof. The salts of regadenoson compound of structural formula I with hydrochloric acid, hydrobromic acid, maleic acid, fumaric acid, succinic acid, sulphuric acid, acetic acid, methanesulfonic acid, tartaric acid or lactic acid may be isolated by the steps of filtration, centrifugation, washing drying and the combinations thereof. The salts of regadenoson compound of structural formula I with hydrochloric acid, hydrobromic acid, maleic acid, fumaric acid, succinic acid, sulphuric acid, acetic acid, methanesulfonic acid, tartaric acid or lactic acid may be further converted into substantially pure regadenoson compound of structural formula I. The salts of regadenoson compound of structural formula 1 with hydrochloric acid, hydrobromic acid, maleic acid, fumaric acid, succinic acid, sulphuric acid, acetic acid, methanesulfonic acid, tartaric acid or lactic acid may be neutralized with inorganic base to get substantially pure regadenoson compound of structural formula I. The examples of inorganic base may include alkali metal hydroxide such as lithium hydroxide, sodium hydroxide or potassium hydroxide, alkali earth metal hydroxide such as calcium hydroxide, magnesium hydroxide, alkali metal carbonate such as lithium carbonate, sodium carbonate, potassium carbonate, alkali earth metal carbonate such as

calcium carbonate, magnesium carbonate, alkali metal bicarbonate such as sodium bicarbonate, potassium bicarbonate. The term "substantially pure regadenoson" means regadenoson having HPLC purity greater than 99.0%. EXAMPLES: In the following example, the preferred embodiment of the present invention is described only by way of illustrating the processes of the invention. However, these are not intended to limit the scope of the present invention in any way. Example no. 1 Preparation of Regadenoson anhydrous crystalline form D. Regadenoson (l0gm) having moisture content 2% was dissolved in an ethanol solvent (100ml) at 50°C and the resulting solution was distilled and azeotrope was isolated for 2 hours. The resulting solution was cooled to -5°C and resulting solids were filtered, washed with anhydrous ethanol (moisture content 0.001% wt/wt) and dried at 50°C under reduced pressure. Yield: 9 gm Moisture content: 0.002% wt/wt Example no. 2 Preparation of Regadenoson hemihydrate crystalline form E. The anhydrous regadenoson (lOgm) was dissolved in butanol (75ml) at 60°C and the resulting solution was stirred for 12 hours and then it was cooled to 20°C and the resulting solids were filtered, washed with butanol (15ml) and dried at 40°C under reduced pressure. Yield: 7.7gm Moisture Content: 2.30% wt/wt

Example no. 3 Preparation of Regadenoson sesquihydrate crystalline form F. The anhydrous regadenoson (l00gm) was dissolved in isopropanol (1250ml) at 40°C and the resulting solution was added water (5ml) and it was stirred for 6 hours at 0°C. The resulting solids were filtered, washed with isopropanol (120ml) and dried at 40°C under reduced pressure. Yield: 86gm Moisture content: 6.5% wt/wt Example no. 4 Preparation of Regadenoson dihydrate crystalline form G. The anhydrous regadenoson (lOOgm) was dissolved in isobutanol (1000ml) at 60°C and the resulting solution was added water (7.5ml) and it was stirred for 9 hours at 25°C. The resulting solids were filtered, washed with isobutanol (50ml) and dried at 40°C under reduced pressure. Yield: 92gm Moisture content: 8.5% wt/wt Example no. 5 Preparation of Regadenoson amorphous form Crystalline regadenoson (15 gm) was dissolved in ethanol (100 ml) at 40°C. The clear solution was subjected to spray drying in a mini spray dryer at an inlet temperature of 60°C and an outlet temperature of 40°C with a feed rate of 15 ml/minute. Regadenoson in an amorphous form was thus isolated. Yield: 7 gm Moisture content: 0.025% wt/wt

Example no. 6 Preparation of Regadenoson hydrochloride The solution of regadenoson (50gm) in ethanol (100ml) was treated with an ethanolic hydrochloride solution (25ml, 10% HC1 wt/wt) at 10°C for 2 hours and resulting solids were filtered, washed with ethanol (20ml) and dried at 40°C to obtain regadenoson hydrochloride salt. Yield: 48gm Purity: 99.89 % (HPLC)

WE CLAIM: 1. Regadenoson crystalline form D characterized by having moisture content less than 0.1% wt/wt. 2. Regadenoson crystalline form E characterized by having moisture content in the range of 2% wt/wt to 2.5% wt/wt. 3. Regadenoson crystalline form F characterized by having moisture content in the range of 6% wt/wt to 7.5% wt/wt. 4. Regadenoson crystalline form G characterized by having moisture content in the range of 8.0% wt/wt to 9.0% wt/wt. 5. Acid addition salts of regadenoson selected from the group comprising of regadenoson hydrochloride, regadenoson hydrobromide, regadenoson maleate, regadenoson fumarate, regadenoson succinate, regadenoson sulfate, regadenoson acetate, regadenoson mesylate, regadenoson tartrate or regadenoson lactate. 6. A pharmaceutical composition comprising crystalline form D, crystalline form E, crystalline form F, crystalline form G or amorphous form of regadenoson. 7. A process of preparing amorphous form of regadenoson by spray-drying or freeze-drying the solution of regadenoson in an organic solvent. 8. The process according to claim no. 7 wherein organic solvent is selected from the group comprising of ketones, alcohols, esters, nitriles, halogenated aliphatic hydrocarbon solvents, ethers or mixtures thereof. 9. Substantially pure regadenoson having HPLC purity greater than 99.0%.

10. A process of preparing substantially pure regadenoson comprising treating Acid addition salts of regadenoson selected from the group comprising of regadenoson hydrochloride, regadenoson hydrobromide, regadenoson maleate, regadenoson fumarate, regadenoson succinate, regadenoson sulfate, regadenoson acetate, regadenoson mesylate, regadenoson tartrate or regadenoson lactate with an inorganic base.

Documents

Sign in to open
Application documents
1 1470-MUM-2011-Other Patent Document-130115.pdf 10 Aug 2018
2 1470-MUM-2011-FORM 5(11-5-2012).pdf 10 Aug 2018
3 1470-mum-2011-form 3.pdf 10 Aug 2018
4 1470-mum-2011-form 2.pdf 10 Aug 2018
5 1470-mum-2011-form 2(title page).pdf 10 Aug 2018
6 1470-MUM-2011-FORM 2(TITLE PAGE)-(11-5-2012).pdf 10 Aug 2018
7 1470-MUM-2011-FORM 2(11-5-2012).pdf 10 Aug 2018
8 1470-MUM-2011-Form 18-130115.pdf 10 Aug 2018
9 1470-mum-2011-form 1.pdf 10 Aug 2018
10 1470-MUM-2011-FER.pdf 10 Aug 2018
11 1470-mum-2011-description(provisional).pdf 10 Aug 2018
12 1470-MUM-2011-DESCRIPTION(COMPLETE)-(11-5-2012).pdf 10 Aug 2018
13 1470-mum-2011-correspondence.pdf 10 Aug 2018
14 1470-MUM-2011-CORRESPONDENCE(11-5-2012).pdf 10 Aug 2018
15 1470-MUM-2011-CLAIMS(11-5-2012).pdf 10 Aug 2018
16 1470-MUM-2011-ABSTRACT(11-5-2012).pdf 10 Aug 2018
17 1470-MUM-2011-OTHERS (MARKED COPY)-140818.pdf 20 Aug 2018
18 1470-MUM-2011-Form 2(Title Page)-140818.pdf 20 Aug 2018
19 1470-MUM-2011-Examination Report Reply Recieved-140818.pdf 20 Aug 2018
20 1470-MUM-2011-Claims-140818.pdf 20 Aug 2018
21 1470-MUM-2011-Amended Pages Of Specification-140818.pdf 20 Aug 2018
22 1470-MUM-2011-Abstract-140818.pdf 20 Aug 2018
23 1470-MUM-2011-Reply to Hearing-100619.pdf 12 Jun 2019
24 1470-MUM-2011-Marked Copy-100619.pdf 12 Jun 2019
25 1470-MUM-2011-Form 30-100619.pdf 12 Jun 2019
26 1470-MUM-2011-Form 2(Title Page)-100619.pdf 12 Jun 2019
27 1470-MUM-2011-Form 1-100619.pdf 12 Jun 2019
28 1470-MUM-2011-Claims-100619.pdf 12 Jun 2019
29 1470-MUM-2011-Amended Pages Of Specification-100619.pdf 12 Jun 2019
30 1470-MUM-2011-Abstract-100619.pdf 12 Jun 2019
31 1470-MUM-2011-PatentCertificate06-05-2022.pdf 06 May 2022
32 1470-MUM-2011-IntimationOfGrant06-05-2022.pdf 06 May 2022
33 396353-Form 4-300822.pdf 02 Sep 2022
34 396353-Correspondence (Renewal)-300822.pdf 02 Sep 2022
35 396353-Form 4-011123.pdf 11 Nov 2023
36 396353-CORRESPONDENCE-011123.pdf 11 Nov 2023
37 396353-CORRESPONDENCE (RENEWAL)-011123.pdf 11 Nov 2023
Search strategy
11470search_12-02-2018.pdf

ERegister / renewals

Ceased
3rd Renewed 30 Aug 2022 Period 13 May 2013 – 13 May 2014 · CBR 22832 · Certificate 24718 ₹4,400
4th Renewed 30 Aug 2022 Period 13 May 2014 – 13 May 2015 · CBR 22832 · Certificate 24718 ₹4,400
5th Renewed 30 Aug 2022 Period 13 May 2015 – 13 May 2016 · CBR 22832 · Certificate 24718 ₹4,400
6th Renewed 30 Aug 2022 Period 13 May 2016 – 13 May 2017 · CBR 22832 · Certificate 24718 ₹4,400
7th Renewed 30 Aug 2022 Period 13 May 2017 – 13 May 2018 · CBR 22832 · Certificate 24718 ₹13,200
8th Renewed 30 Aug 2022 Period 13 May 2018 – 13 May 2019 · CBR 22832 · Certificate 24718 ₹13,200
9th Renewed 30 Aug 2022 Period 13 May 2019 – 13 May 2020 · CBR 22832 · Certificate 24718 ₹13,200
10th Renewed 30 Aug 2022 Period 13 May 2020 – 13 May 2021 · CBR 22832 · Certificate 24718 ₹13,200
11th Renewed 30 Aug 2022 Period 13 May 2021 – 13 May 2022 · CBR 22832 · Certificate 24718 ₹26,400
12th Renewed 30 Aug 2022 Period 13 May 2022 – 13 May 2023 · CBR 22832 · Certificate 24718 ₹26,400
13th Renewed 01 Nov 2023 Period 13 May 2023 – 13 May 2024 · CBR 44701 · Certificate 45090 ₹26,400